Department of Pathophysiology, Wuhan University School of Medicine, Hubei, Wuhan, China.
School of Medicine, King Faisal University, Al-Ahsa, Kingdom of Saudi Arabia.
Curr Probl Cardiol. 2021 Oct;46(10):100842. doi: 10.1016/j.cpcardiol.2021.100842. Epub 2021 Mar 19.
Although the respiratory system is the main target of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it is evident from recent data that other systems, especially cardiovascular and hematological, are also significantly affected. In fact, in severe form, COVID-19 causes a systemic illness with widespread inflammation and cytokine flood, resulting in severe cardiovascular injury. Therefore, we reviewed cardiac injury biomarkers' role in various cardiovascular complications of COVID 19 in recent studies.
Cardiac injury biomarkers were elevated in most of the complicated cases of COVID-19, and their elevation is directly proportional to the worst outcome. Evaluation of cardiac biomarkers with markers of other organ damage gives a more reliable tool for case fatalities and future outcome.
Significant association of cardiac biomarkers in COVID-19 cases helps disease management and prognosis, especially in severely ill patients.
虽然呼吸系统是严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的主要靶器官，但最近的数据表明，其他系统，特别是心血管和血液系统，也受到明显影响。事实上，在严重形式下，COVID-19 导致全身性疾病，广泛炎症和细胞因子泛滥，导致严重的心血管损伤。因此，我们在最近的研究中综述了心脏损伤生物标志物在 COVID-19 各种心血管并发症中的作用。
在 COVID-19 的大多数复杂病例中，心脏损伤生物标志物升高，其升高与最差的结果成正比。用其他器官损伤标志物评估心脏标志物为病死率和未来预后提供了更可靠的工具。
COVID-19 病例中心脏生物标志物的显著相关性有助于疾病管理和预后，特别是在重症患者中。
